Alere Inc (ALR.N)

ALR.N on New York Stock Exchange

34.29USD
12:54pm EDT
Price Change (% chg)

$0.13 (+0.38%)
Prev Close
$34.16
Open
$34.20
Day's High
$34.60
Day's Low
$34.04
Volume
121,631
Avg. Vol
150,825
52-wk High
$35.35
52-wk Low
$17.13

ALR.N

Chart for ALR.N

About

Alere Inc. is a provider of point-of-care diagnostics and services. The Company's products and services help healthcare practitioners make treatment decisions and improve outcomes for individuals living with chronic disease. The Company's portfolio also includes a range of health information solutions that access to critical... (more)

Overall

Beta: 1.59
Market Cap (Mil.): $2,778.50
Shares Outstanding (Mil.): 81.34
Dividend: --
Yield (%): --

Financials

  ALR.N Industry Sector
P/E (TTM): -- 67.23 37.87
EPS (TTM): -1.68 -- --
ROI: -2.00 5.02 18.70
ROE: -7.52 9.82 19.53
Search Stocks

Activist investor sees Alere shares soaring if asset sales plan adopted

NEW YORK - An activist shareholder, which has been battling Alere Inc's management, said investors could more than double the value of their stock if they backed a plan for the health diagnostics and services provider to offload assets.

08 Jul 2013

Activist investor sees Alere shares soaring if asset sales plan adopted

NEW YORK, July 8 - An activist shareholder, which has been battling Alere Inc's management, said investors could more than double the value of their stock if they backed a plan for the health diagnostics and services provider to offload assets.

08 Jul 2013

Exclusive: Activist investor sends Alere letter calling for unit sales

NEW YORK - An activist investor who has been campaigning for change at Alere Inc sent the company a letter on Monday calling for the health diagnostics and services company to sell three of its businesses, which it believes can yield more than $3 billion in proceeds.

10 Jun 2013

Activist investor wants Alere to explore $2.5 billion unit sale: sources

NEW YORK - An activist investor in Alere Inc wants the health diagnostics and services company to explore a sale of its drug testing business, which it believes could fetch as much as $2.5 billion and help Alere pay down debt, two people familiar with the matter said on Tuesday.

21 May 2013

Activist investor wants Alere to explore $2.5 bln unit sale -sources

NEW YORK, May 21 - An activist investor in Alere Inc wants the health diagnostics and services company to explore a sale of its drug testing business, which it believes could fetch as much as $2.5 billion and help Alere pay down debt, two people familiar with the matter said on Tuesday.

21 May 2013

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$15.00
Provider: Zacks Investment Research Inc.
$12.00
Provider: Zacks Investment Research Inc.
$12.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks